Month: May 2024

FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Name of exempt principal trader: Investec Bank plc(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree Alpha Financial Markets Consulting plc(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Joint Broker to Alpha Financial Markets Consulting plc(d)        Date dealing undertaken:1st May 2024(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If...

The council of Nordecon AS has adopted a decision to appoint Maret Tambek as the chairman of the company’s management board from 01 May 2024 with the term of office of three years. From 08 January 2024, Maret Tambek acted as acting chairman of the management board of Nordecon AS. The management board of Nordecon AS will continue with three members: Maret Tambek (chairman), Tarmo Pohlak and Priit Luman. Nordecon (www.nordecon.com) is a group of construction companies whose core business is construction project management and general contracting in the buildings and infrastructures segment. Geographically the Group operates in Estonia, Ukraine and Sweden. The parent of the Group is Nordecon AS, a company registered and located in Tallinn, Estonia. The consolidated revenue of the Group in 2023 was 278 million euros. Currently Nordecon...

Amsterdam 2 May 2024, 8 AM CET. Cabka N.V. (together with its subsidiaries “Cabka”, or the “Company”), a company specialized in transforming hard to recycle plastic waste into innovative Reusable Transport Packaging (RTP), listed at Euronext Amsterdam, announces that its Supervisory Board will nominate Alexander Masharov (1980) for appointment by the shareholders of Cabka as member of the Management Board and Chief Executive Officer. If appointed, Alexander will succeed Tim Litjens, who announced in March 2024 his intention to step down and leave Cabka by the end of the third quarter 2024. An Extraordinary General Meeting of Shareholders shall be convened in due course to resolve on the appointment. If appointed, Alexander Masharov will join Cabka NV as of 1 August 2024 to allow for a seamless CEO succession. Cabka’s strategic goals remain...

Alm. Brand Group upgrades guidance for pre-tax profit by DKK 100 millionAlm. Brand Group’s insurance service result was a profit of DKK 295 million (Q1 2023: DKK 205 million), driven in particular by sustained favourable trends in Commercial Lines Insurance revenue grew at a highly satisfactory rate of 5.6% to DKK 3,012 million (Q1 2023: DKK 2,853 million), driven in particular by strong growth of 8.6% in Personal Lines The underlying claims experience improved by 3.0 percentage points to 61.0, driven by a strong performance in Commercial Lines and favourable developments in Personal Lines despite a sustained high frequency of motor claims The implementation of synergy initiatives is progressing according to plan and generated a positive accounting effect of DKK 98 million in Q1 2024. The expense ratio was 19.1 (Q1 2023: 20.0) Highly...

PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine,an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., May 02, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces eight posters, including two mini oral symposia, on additional analyses from its successful Phase 3 ENHANCE studies with ensifentrine for the treatment of chronic obstructive pulmonary disease (“COPD”) will be presented at the American Thoracic Society International Conference (“ATS”) 2024. Pooled analysis demonstrating reductions in the rate and risk of exacerbations with ensifentrine will be presented as part of the ‘Late Breaking Mini Symposium’ designed to highlight new breakthroughs. The posters...